Levofloxacin Aurovitas (Levofloxacin)

Levofloxacin is a fluoroquinolone antibiotic indicated for several bacterial infections affecting the respiratory, urinary and integumentary systems.

• Community‑acquired pneumonia: eradicates the causative bacteria, leading to clinical improvement and resolution of pulmonary infiltrates.
• Acute bacterial sinusitis: reduces sinus inflammation by eliminating the infecting organisms and relieving congestion.
• Acute exacerbations of chronic bronchitis: controls bacterial overgrowth, decreasing cough and sputum production.
• Uncomplicated urinary tract infections: clears the uropathogen, resulting in symptom relief and prevention of recurrence.
• Skin and soft tissue infections: targets common skin pathogens, promoting healing of cellulitis, abscesses and wound infections.

• Levofloxacin exerts its antibacterial activity by binding to bacterial DNA gyrase (topoisomerase II) and topoisomerase IV. This inhibition prevents the supercoiling and relaxation of DNA required for replication and transcription, leading to bacterial cell death. The dual targeting of both enzymes enhances its potency against Gram‑negative and Gram‑positive organisms, including many resistant strains. Consequently, bacterial proliferation is halted, allowing the immune system to clear the infection.

Levofloxacin may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects

• Nausea
• Diarrhea
• Headache
• Dizziness
• Insomnia
• Rash

Serious or Rare Side Effects

• Tendon rupture or tendinitis
• Peripheral neuropathy
• QT interval prolongation
• Severe allergic reactions (anaphylaxis, Stevens‑Johnson syndrome)
• Clostridioides difficile‑associated diarrhea
• Hepatic dysfunction or elevated liver enzymes

When prescribing Levofloxacin, clinicians should observe several precautionary measures to minimize risk.

• Assess renal function: adjust dose in patients with impaired clearance.
• Evaluate hypersensitivity: avoid in individuals with known fluoroquinolone allergy.
• Use caution in elderly: increased susceptibility to tendon injury and CNS effects.
• Monitor for tendon pain: discontinue if pain, swelling or inflammation occurs.
• Avoid concomitant QT‑prolonging drugs: reduce risk of cardiac arrhythmias.
• Store at ambient temperature: keep in original packaging, protect from moisture and light.

Levofloxacin interacts with several drug classes; some combinations should be avoided while others require close monitoring.

Major Interactions (Avoid)

• Antacids or supplements containing magnesium, aluminum, calcium, or iron: markedly reduce absorption.
• Warfarin: may enhance anticoagulant effect, increasing bleeding risk.
• Non‑steroidal anti‑inflammatory drugs (NSAIDs): increase risk of CNS stimulation and seizures.
• Cyclosporine: elevated cyclosporine levels may occur, raising nephrotoxicity risk.
• Theophylline: plasma concentrations can rise, leading to toxicity.

Moderate Interactions (Monitor Closely)

• Oral contraceptives: efficacy may be reduced, consider alternative contraception.
• Corticosteroids: combined use may heighten risk of tendon rupture.
• Antidiabetic agents (e.g., sulfonylureas): blood glucose may drop, monitor levels.
• HIV protease inhibitors: may increase levofloxacin exposure, adjust dose if needed.
• Diabetic agents: potential hypoglycemia, require glucose monitoring.